CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Generic: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Solco Healthcare LLCManufacturer
ORALRoute
CANDESARTAN CILEXETILActive Substance
2018-04-11Original Approval
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE is FDA application ANDA207455, sponsored by PRINSTON. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2021-09-13
Candesartan Cilexetil Tablets, USP 16 mg, 30 count bottles, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WVFailed Impurities/Degradation Specifications; out of specification for Related Compound
Class III2020-10-02
Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002Out-of-specification organic impurity results obtained during routine stability testing.
Top Reported Reactions
1
DYSPNOEA
1,024 reports
2
FATIGUE
942 reports
3
HEADACHE
897 reports
4
OFF LABEL USE
889 reports
5
NAUSEA
864 reports
6
DIZZINESS
812 reports
7
DIARRHOEA
783 reports
8
DRUG INEFFECTIVE
777 reports
9
VOMITING
734 reports
10
PAIN
733 reports